



OPEN ACCESS

EDITED AND REVIEWED BY

M. Pilar Francino,
Fundación para el Fomento de la
Investigación Sanitaria y Biomédica de
la Comunitat Valenciana
(FISABIO), Spain

*CORRESPONDENCE

Yubin Luo
✉ luoyubin2016@163.com
Yi Liu
✉ yi2006liu@163.com

†These authors have contributed
equally to this work

SPECIALTY SECTION

This article was submitted to
Microbial Symbioses,
a section of the journal
Frontiers in Microbiology

RECEIVED 16 November 2022

ACCEPTED 30 November 2022

PUBLISHED 12 December 2022



CITATION

Huang T, Pu Y, Wang X, Li Y, Yang H,
Luo Y and Liu Y (2022) Corrigendum:
Metabolomic analysis in
spondyloarthritis: A systematic review.
Front. Microbiol. 13:1100290.
doi: 10.3389/fmicb.2022.1100290

COPYRIGHT

© 2022 Huang, Pu, Wang, Li, Yang,
Luo and Liu. This is an open-access
article distributed under the terms of
the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Metabolomic analysis in spondyloarthritis: A systematic review

Tianwen Huang^{1,2,3†}, Yaoyu Pu^{1,2,3†}, Xiangpeng Wang^{1,2,3},
Yanhong Li^{1,2,3}, Hang Yang^{1,2,3}, Yubin Luo ^{1,2,3*} and
Yi Liu ^{1,2,3*}

¹Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China, ²Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China, ³Institute of Immunology and Inflammation, Frontiers Science Center for Disease Related Molecular Network, West China Hospital, Chengdu, China

KEYWORDS

spondyloarthritis, ankylosing spondylitis, metabolomics, biomarkers, dysbiosis

A corrigendum on

[Metabolomic analysis in spondyloarthritis: A systematic review](#)

by Huang, T., Pu, Y., Wang, X., Li, Y., Yang, H., Luo, Y., and Liu, Y. (2022). *Front. Microbiol.* 13:965709. doi: 10.3389/fmicb.2022.965709

In the published article, there was an error. We mistakenly described the trend of changes in the levels of some metabolites after treatment of SpA patients.

A correction has been made to **Results**, “*Dynamic alterations in the metabolic profile before and after treatment of spondyloarthritis*,” Paragraphs 2 and 4. These sentences previously stated:

“[Kapoor et al. \(2013\)](#) and [Bogunia-Kubik et al. \(2021\)](#) found elevated levels of isobutyrate and acetone in AS as well as elevated levels of acetate in PsA after TNFi therapy. Decreased levels of amino acids, including histidine, leucine and phenylalanine, were also found in AS patients after therapy. Another study including PsA patients receiving TNFi therapy showed higher levels of glutamine than those observed at baseline. Additionally, the two studies both found decreased creatine and creatinine levels in SpA patients after treatment.”

And

“In addition, in the serum of JIA patients, MTX therapy increased the level of omega-3 unsaturated fatty acids (docosahexanoic acid and linoleic acid), which are anti-inflammatory mediators.”

The corrected sentence appears below:

“[Kapoor et al. \(2013\)](#) and [Bogunia-Kubik et al. \(2021\)](#) found decreased levels of isobutyrate and acetone in AS as well as decreased levels of acetate in PsA after TNFi therapy. Elevated levels of amino acids, including histidine, leucine and phenylalanine, were also found in AS patients after therapy. Another study including PsA patients receiving TNFi therapy showed lower levels of glutamine than those observed at baseline. Additionally, the two studies both found elevated creatine and creatinine levels in SpA patients after treatment.”

And

“In addition, in the serum of JIA patients, MTX therapy reduced the level of omega-3 unsaturated fatty acids (docosahexanoic acid and linoleic acid), which are anti-inflammatory mediators.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Bogunia-Kubik, K., Wojtowicz, W., Swierkot, J., Mielko, K. A., Qasem, B., Wielinska, J., et al. (2021). Disease differentiation and monitoring of anti-TNF treatment in rheumatoid arthritis and spondyloarthropathies. *Int. J. Mol. Sci.* 22:7389. doi: 10.3390/ijms22147389

Kapoor, S. R., Buckley, C. D., Raza, K., Filer, A., Fitzpatrick, M. A., Young, S. P., et al. (2013). Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis. *Arthritis Rheum.* 65, 1448–1456. doi: 10.1002/art.37921